Abstract
Atopic dermatitis (AD) is a heterogeneous disease and characterized by dysregulated immune response of diverse immune cell subtypes, such as Th2, Th22, and Th17. Heterogeneity of AD can be reasoned by varying contribution of underlying immune subsets, as observed by altered cytokine milieus in the skin. These variations result in changes of protein expression in keratinocytes, including antimicrobial peptides (AMPs). We hypothesize that antimicrobial peptide expression may correlate with the underlying immune subtypes and, therefore, can be used as potential biomarkers to predict treatment outcome.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
